Chairman of the Board
Olivier joined the Andera Partners’ Life Sciences team based in Paris in 2006. Before that he worked with 3i in Venture Healthcare, first investing out of Munich, later out of Paris. Prior to that, Olivier was a consultant with Mercer Management Consulting in Munich and Paris. Olivier holds a PhD in Biology from the Munich Institute für Genetik und Mikrobiology and has performed his scientific research in Munich and Oxford University.
Olivier is a Director of Allecra Therapeutics, JenaValve Technologies, MMI, Autonomic Technologies and MedLumics, and was a director of Novexel, Endosense, Sapiens and Probiodrug , SuperSonic Imagine and Noxxon Pharma up until their respective acquisitions or listings.
Dr Daniel O’Mahony is a Partner at the pan European life sciences VC Seroba Life Sciences, investing in companies developing new medical devices or therapeutics.
Daniel brings a wealth of experience in product development, strategic planning, licensing, intellectual property management and commercialization across the Medtech, pharma and biotech industry sectors and in both venture capital and corporate venture investments. He previously worked in Elan Corporation plc and had also established the Technology Transfer Office at NUI, Galway.
Daniel graduated with a Ph.D. from the National University of Ireland, Cork and holds a business degree in technology management from the Smurfit Business School, UCD. He has held academic appointments at the Genetics Department, Trinity College, Dublin, the Weis Research Centre, Geisinger Clinic, Pennsylvania, USA and the Department of Medicine & Experimental Therapeutics at UCD. He has published in several scientific journals, is co-inventor on numerous patent families and is a regular panel member at major international medtech conferences.
Dr O’Mahony currently sits on the boards of Atlantic Therapeutics, Medlumics, Novate Medical and PQ Bypass. He also sat on the boards of Apica Cardiovascular (acquired by Thoratec, 2014), Covagen (acquired by Cilag/Janssen Pharmaceutical companies of the Johnson & Johnson Group, 2014), Stokes Bio (acquired by Life Technologies) and Straatum (acquired by Lam Research Corporation).
Claudio Rumazza is a venture capital investor, Partner at Innogest Capital, where he focuses on healthcare investments and in particular on medical devices, diagnostics and digital health.
Claudio currently serves on the Board or as investor observer of Erydel SpA, Newronika Srl, Anaconda Biomed SA, Angiodroid Srl, Pi-Cardia Ltd and CVLab SpA.
Prior to Innogest, Claudio held various positions as a corporate finance executive at Finn-Power Group and Prima Industrie Group and he stated his career as a management consultant.
Claudio has a bachelor’s degree economics from the University of Torino.
Raúl Martin-Ruíz, PhD
Raúl Martín-Ruiz is a Principal in Ysios Capital, a leading independent Spanish venture capital firm that provides private equity financing to human healthcare and life sciences companies. Prior to joining Ysios in 2008 he developed his career in Laboratorios Almirall, initially working in corporate business development (Licensing In and Licensing Out) and then as responsible for developing and managing the business of the company in the Americas and Africa through licensees and distributors.
Initially he was trained as a researcher in the areas of Central Nervous System pharmacology in the Department of Pharmacology of the UPV-EHU (University of the Basque Country), and in neurochemistry in the Department of Neurochemistry of the IIBB-CSIC (Institute for Biomedical Research of Barcelona-Spanish National Research Council).
Other than MedLumics, he is a Member of the Board of Directors of CorWave and Anaconda Biomed, and formerly of STAT-Dx (acquired by Qiagen) and Prexton Therapeutics (acquired by Lundbeck). He has a B.Sc. in Biological Sciences by the UPV-EHU and holds a Ph.D. in Neurosciences by the same university and the CSIC.
James Leon Greene
Jim serves as Chief Executive Officer and a member of the Board of Directors for MedLumics bringing 30 years of extensive operational experience in medical device design, development, and commercialization.
Prior to joining MedLumics, Jim served as Partner in Seroba Life Sciences Limited, a Dublin based venture capital firm. Jim is a serial entrepreneur founding multiple medical device start-ups in the cardiovascular field serving as CEO of Verso Technologies, Inc., Apica Cardiovascular Ltd., Advanced Medical Technologies, Inc. (APK), and MitralSolutions, Inc. Earlier in his career, Jim held Director level positions at global medical device companies such as Medtronic, AVE, and Guidant.
Jim is a member of the Wallace Coulter Foundation Oversight committee in Atlanta, Georgia, where he participates in mentoring new entrepreneurs in their development of university-based technologies into successful medical device companies.
Jim holds a B.A. degree from Furman University, Greenville, S.C. and served in the United States Military following graduation for 7 years.
Giovanni Leo joined the venture capital firm Innogest Capital in mid – 2017 as Venture Partner. Prior to Innogest Giovanni was VP of R&D at St Jude Medical since the acquisition of Endosense in 2013, which he co-founded to develop a novel technology for the catheter ablation treatment of cardiac arrhythmias.
Formerly he was the director of the Geneva offices for Acrostak Corp., a Boston-Scientific funded medical device company that developed the only European system for vascular brachytherapy. He was also co-founder of Isotopes and Metals Ltd., an emerging medical device company focused on technology for prostate and gynecological brachytherapy. Giovanni previously held a software quality manager position at LeCroy Corp. as well as a CERN fellowship to carry out development activity for the control system of the Large Hadron Collider (LHC).
Giovanni earned an Executive MBA in Management and Corporate Finance from the HEC of Lausanne, following a degree in management engineering from Politecnico of Milano, Italy.
Eduardo Margallo, PhD
Eduardo Margallo obtained his M.Eng. degree in Telecommunications from the Polytechnic University of Madrid, a M.Sc. Degree in Physics from UNED and a M.Eng. degree in Electrical Engineering (Dipl.-Ing. Elektrotechnik) from the University of Stuttgart (Germany). He completed his doctorate at Delft University of Technology (The Netherlands) in the area of biophotonic instrumentation.
He has accumulated 8 years of experience in the design and manufacturing of biophotonic instrumentation and integrated optics, with in-depth knowledge of the physics of light propagation in tissue, sensor microfabrication techniques and silicon photonic devices. During this time he participated in the definition and implementation of clinically driven research projects in collaboration with several universities and hospitals in the Netherlands and Italy.
Eduardo co-founded MedLumics in 2009 and is currently its Chief Operations Officer, having guided the company through its seed and start-up phases. In particular, he led fund-raising activities resulting in a 34,4M€ B-Round closed in March 2017.